Low-Dose Busulfan Reduces Human CD34

busulfan c-kit erythropoiesis gene therapy hematopoietic stem cell transplantation immunodeficient mice xenograft transplantation

Journal

Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857

Informations de publication

Date de publication:
13 Dec 2019
Historique:
received: 06 08 2019
accepted: 30 10 2019
entrez: 1 1 2020
pubmed: 1 1 2020
medline: 1 1 2020
Statut: epublish

Résumé

Humanized animal models are central to efforts aimed at improving hematopoietic stem cell (HSC) transplantation with or without genetic modification. Human cell engraftment is feasible in immunodeficient mice; however, high HSC doses and conditioning limit broad use of xenograft models. We assessed human CD45

Identifiants

pubmed: 31890735
doi: 10.1016/j.omtm.2019.10.017
pii: S2329-0501(19)30125-1
pmc: PMC6909187
doi:

Types de publication

Journal Article

Langues

eng

Pagination

430-437

Références

Mol Ther Methods Clin Dev. 2015 Dec 02;2:15045
pubmed: 26665131
Mol Ther Methods Clin Dev. 2019 Jan 25;13:187-196
pubmed: 30788387
Stem Cells Dev. 2017 Jan 15;26(2):71-76
pubmed: 27750026
Blood. 2010 Jul 15;116(2):193-200
pubmed: 20404133
J Virol. 2009 Oct;83(19):9854-62
pubmed: 19625395
Mol Ther Nucleic Acids. 2013 Sep 17;2:e122
pubmed: 24045711
Blood. 2014 May 15;123(20):3105-15
pubmed: 24622326
J Clin Invest. 2013 Jul 1;:null
pubmed: 23863630
Nat Methods. 2009 Apr;6(4):267-9
pubmed: 19270698
Stem Cell Reports. 2016 Oct 11;7(4):591-601
pubmed: 27618723
J Immunol. 2005 May 15;174(10):6477-89
pubmed: 15879151
Nat Protoc. 2018 Feb;13(2):358-376
pubmed: 29370156
Trends Immunol. 2018 Sep;39(9):748-763
pubmed: 30077656
Gene Ther. 2011 Nov;18(11):1078-86
pubmed: 21544097
Int J Hematol. 2003 Jun;77(5):456-62
pubmed: 12841383
Blood. 1997 Jun 1;89(11):4013-20
pubmed: 9166840
Stem Cell Reports. 2015 Feb 10;4(2):171-80
pubmed: 25601207
Blood. 2012 Jan 19;119(3):717-26
pubmed: 22101896
Cell Transplant. 2010;19(11):1465-73
pubmed: 21214970
Clin Immunol. 2010 Apr;135(1):84-98
pubmed: 20096637
Am J Hematol. 2017 Sep;92(9):E513-E519
pubmed: 28568895
Mol Ther. 2019 Aug 7;27(8):1389-1406
pubmed: 31178391
Stem Cells. 2009 Jan;27(1):175-82
pubmed: 18927475
Mol Ther Methods Clin Dev. 2018 Nov 01;11:167-179
pubmed: 30533448
Bone Marrow Transplant. 2013 Oct;48(10):1335-41
pubmed: 23604009
Exp Hematol. 2007 Sep;35(9):1415-20
pubmed: 17618036
Science. 2007 Nov 23;318(5854):1296-9
pubmed: 18033883
Br J Haematol. 2019 Jul;186(2):286-299
pubmed: 30972754
Hum Gene Ther. 2018 Oct;29(10):1153-1166
pubmed: 30198339
Mol Ther Methods Clin Dev. 2017 Jan 11;4:137-148
pubmed: 28344999
J Immunol. 2008 Feb 15;180(4):2045-53
pubmed: 18250409
Blood. 2012 Apr 12;119(15):3629-37
pubmed: 22374698
Blood. 2015 Apr 23;125(17):2597-604
pubmed: 25733580
Clin Cancer Res. 2008 Apr 1;14(7):1926-30
pubmed: 18381929
Cell Stem Cell. 2014 Aug 7;15(2):227-38
pubmed: 25017720
Stem Cell Reports. 2016 Sep 13;7(3):425-438
pubmed: 27499200

Auteurs

Alexis Leonard (A)

Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Morgan Yapundich (M)

Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Tina Nassehi (T)

Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Jackson Gamer (J)

Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Claire M Drysdale (CM)

Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Juan J Haro-Mora (JJ)

Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Selami Demirci (S)

Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Matthew M Hsieh (MM)

Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Naoya Uchida (N)

Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

John F Tisdale (JF)

Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.

Classifications MeSH